242 related articles for article (PubMed ID: 31481549)
1. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Tandogdu Z; Lewis R; Duncan A; Penegar S; McDonald A; Vale L; Shen J; Kelly JD; Pickard R; N Dow J; Ramsay C; Mostafid H; Mariappan P; Nabi G; Creswell J; Lazarowicz H; McGrath J; Taylor E; Clark E; Maclennan G; Norrie J; Hall E; Heer R;
BMJ Open; 2019 Sep; 9(9):e022268. PubMed ID: 31481549
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.
Yu G; Rice S; Heer R; Lewis R; Vadiveloo T; Mariappan P; Penegar S; Clark E; Tandogdu Z; Hall E; Vale L
Eur Urol Open Sci; 2023 Jul; 53():67-77. PubMed ID: 37441343
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
[TBL] [Abstract][Full Text] [Related]
7. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
10. 'Real-life experience': recurrence rate at 3 years with Hexvix
Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
[TBL] [Abstract][Full Text] [Related]
11. Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).
Miyake M; Nishimura N; Inoue T; Suzuki S; Fujii T; Owari T; Hori S; Nakai Y; Toritsuka M; Nakagawa H; Tsukamoto S; Anai S; Torimoto K; Yoneda T; Tanaka N; Fujimoto K
Trials; 2021 Feb; 22(1):136. PubMed ID: 33579327
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
[TBL] [Abstract][Full Text] [Related]
13. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
[TBL] [Abstract][Full Text] [Related]
14. Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Nishimura N; Miyake M; Nakahama T; Miyamoto T; Nishimoto K; Oyama M; Matsushita Y; Miyake H; Fukuhara H; Inoue K; Kobayashi K; Matsumoto H; Matsuyama H; Fujii T; Hirao Y; Fujimoto K
Int J Urol; 2023 Dec; 30(12):1112-1119. PubMed ID: 37605814
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
17. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): Cost impact of transurethral resection of bladder tumor in Japan.
Fukuhara H; Hagiwara Y; Oba K; Inoue K
Photodiagnosis Photodyn Ther; 2023 Dec; 44():103758. PubMed ID: 37604217
[TBL] [Abstract][Full Text] [Related]
19. Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
Green DA; Rink M; Cha EK; Xylinas E; Chughtai B; Scherr DS; Shariat SF; Lee RK
BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598
[TBL] [Abstract][Full Text] [Related]
20. The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
Nishimura N; Miyake M; Miyamoto T; Tomizawa M; Shimizu T; Morizawa Y; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Jpn J Clin Oncol; 2023 Mar; 53(4):343-348. PubMed ID: 36585780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
